Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AB-205 in Lymphoma Undergoing HDT-ASCT
NCT03925935Phase 1Completed
- Sponsor
- Angiocrine Bioscience
- Start
- May 2019
- Primary completion
- Nov 2020
- Modality
- CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of E-CEL UVEC in Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL), sponsored by Angiocrine Bioscience. Primary endpoint: Occurrence of adverse events grade >= 3 as assessed by CTCAEv5 at 24 hours. Started May 2019; status: completed.
02
Drugs
E-CEL UVEC
03
Conditions
Hodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT03925935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03925935.